Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Am J Hematol. 2011 Sep;86(9):811–819. doi: 10.1002/ajh.22097

Table II.

Demographics and Efficacy of Nilotinib (ENESTnd trial)

Nilotinib 300mg twice daily (n= 282) Nilotinib 400mg twice daily (n= 281) Imatinib 400mg once daily (n=283)
Median duration of treatment 13.8 months 13.8 months 13.8 months

Median age Range 47 years (18-85 years) 47 years (18-81 years) 46 years (18-80 years)

Sokal Risk (%)
Low 37 37 37
Intermediate 36 36 36
High 28 28 28

Prior Imatinb (%) 13 9 11

MMR (%)
    By 6 months 44 43 22 (P<0.001, <0.001)
    By 12 months 55 51 27 (P<0.001, <0.001)
Confirmed CCyR (%)
    By 6 months 67 63 45 (P=NR)
    By 12 months 80 78 72 (P<0.0001, <0.0005)

(Adapted, with permission, from Saglio et al, Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia, NEngl J Med, 2010;362:2251-2259)